Added to YB: 2026-06-12
Pitch date: 2026-06-10
SRRK [neutral]
Scholar Rock Holding Corporation
+1.29%
current return
Author Info
No bio for this author
Company Info
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
Market Cap
$5.3B
Pitch Price
$44.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-12.54
P/E
-12.85
EV/Sales
N/A
Sector
Biotechnology
Category
growth
GS Healthcare Conference – Recap part 1 (Day 2) - Scholar Rock Holding Corporation
SRRK (overview): Muscle biology platform, $45.30. Lead apitegromab first successful myostatin blocker; positive Ph3 SAPPHIRE SMA motor data, broad eligibility (age 2+), FDA date Sept 30 2026 = launch catalyst. FSHD expansion via FORGE Ph2, data 2027-28. Cash runway covers full commercialization. M&A Score 80, Growth 76.
Read full article (1 min)